GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...

“But GSK is showing strength elsewhere in its portfolio with 19% growth in ... settlement to resolve tens of thousands of lawsuits in the US over its discontinued heartburn drug Zantac earlier in ...

And as recently announced, we have expedited retiring the risk for Zantac. We expect this to result ... And then we've got the oncology strength coming from Jemperli expanded population and ...

“But GSK is showing strength elsewhere in its portfolio with ... of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October.

Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales. Traumatised investors require a long period of peace and ...

Within these costs we have included the likely payouts related to the increasingly concerning Zantac litagation ... should hold ample balance sheet strength to support opportunistic acquisitions ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.